Jon Hamilton
Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.
In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.
Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.
Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.
In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.
Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.
From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.
Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.
-
There's growing evidence that a lack of deep sleep increases the risk of Alzheimer's disease. Scientists say that's because during deep sleep, the brain removes toxins associated with Alzheimer's.
-
A Food and Drug Administration advisory committee voted that studies of the drug aducanumab for Alzheimer's treatment don't show it's effective.
-
Psilocybin, the hallucinogenic substance found in "magic" mushrooms, appears to relieve the symptoms of major depression.
-
Many memories are like short movies. People relive experiences such as arriving for the first day of school or falling off a bike. Scientists have shown how the brain organizes these episodes.
-
Researchers launched a major study of an experimental Alzheimer's drug this summer. They also learned a lot about how to protect participants who must make frequent visits to a medical center.
-
Scientists have identified specialized brain cells that create two distinct kinds of thirst. Some cells respond to a need for water alone, while others produce a craving for water and salt.
-
People of African ancestry have been excluded from many studies of brain disorders. In Baltimore, scientists, doctors and community leaders are working to make neuroscience research more diverse.
-
Researchers were able to mimic the mind-altering effects of the drug ketamine by inducing a particular rhythm in one area of the brain.
-
An experimental drug let mice spend a month in the International Space Station's near-zero gravity without losing mass. It could help people spend years in space without major health consequences.
-
Distance learning is a big challenge for many students with attention deficit hyperactivity disorder and other learning disabilities. And making it work often requires parents to become educators.
-
Doctors have a new option for suicidal patients. It's a fast-acting nasal spray containing a version of the anesthetic ketamine.
-
The Food and Drug Administration has approved a fast-acting nasal spray to treat suicidal patients. The spray contains a chemical cousin of the anesthetic and party drug ketamine.